Cargando…

Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study

OBJECTIVE: To test the hypothesis that the use of chondroitin sulfate (CS) or glucosamine reduces the risk of acute myocardial infarction (AMI). DESIGN: Case-control study nested in a primary cohort of patients aged 40 to 99 years, using the database BIFAP during the 2002–2015 study period. From thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzucchelli, Ramón, Rodríguez-Martín, Sara, García-Vadillo, Alberto, Gil, Miguel, Rodríguez-Miguel, Antonio, Barreira-Hernández, Diana, García-Lledó, Alberto, de Abajo, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274913/
https://www.ncbi.nlm.nih.gov/pubmed/34252115
http://dx.doi.org/10.1371/journal.pone.0253932
_version_ 1783721626639007744
author Mazzucchelli, Ramón
Rodríguez-Martín, Sara
García-Vadillo, Alberto
Gil, Miguel
Rodríguez-Miguel, Antonio
Barreira-Hernández, Diana
García-Lledó, Alberto
de Abajo, Francisco J.
author_facet Mazzucchelli, Ramón
Rodríguez-Martín, Sara
García-Vadillo, Alberto
Gil, Miguel
Rodríguez-Miguel, Antonio
Barreira-Hernández, Diana
García-Lledó, Alberto
de Abajo, Francisco J.
author_sort Mazzucchelli, Ramón
collection PubMed
description OBJECTIVE: To test the hypothesis that the use of chondroitin sulfate (CS) or glucosamine reduces the risk of acute myocardial infarction (AMI). DESIGN: Case-control study nested in a primary cohort of patients aged 40 to 99 years, using the database BIFAP during the 2002–2015 study period. From this cohort, we identified incident cases of AMI and randomly selected five controls per case, matched by exact age, gender, and index date. Adjusted odds ratios (AOR) and 95% confidence interval (CI) were computed through a conditional logistic regression. Only new users of CS or glucosamine were considered. RESULTS: A total of 23,585 incident cases of AMI and 117,405 controls were included. Of them, 89 cases (0.38%) and 757 controls (0.64%) were current users of CS at index date, yielding an AOR of 0.57 (95%CI: 0.46–0.72). The reduced risk among current users was observed in both short-term (<365 days, AOR = 0.58; 95%CI: 0.45–0.75) and long-term users (>364 days AOR = 0.56; 95%CI:0.36–0.87), in both sexes (men, AOR = 0.52; 95%CI:0.38–0.70; women, AOR = 0.65; 95%CI:0.46–0.91), in individuals over or under 70 years of age (AOR = 0.54; 95%CI:0.38–0.77, and AOR = 0.61; 95%CI:0.45–0.82, respectively) and in individuals at intermediate (AOR = 0.65; 95%CI:0.48–0.91) and high cardiovascular risk (AOR = 0.48; 95%CI:0.27–0.83), but not in those at low risk (AOR = 1.11; 95%CI:0.48–2.56). In contrast, the current use of glucosamine was not associated with either increased or decreased risk of AMI (AOR = 0.86; 95%CI:0.66–1.08). CONCLUSIONS: Our results support a cardioprotective effect of CS, while glucosamine seems to be neutral. The protection was remarkable among subgroups at high cardiovascular risk.
format Online
Article
Text
id pubmed-8274913
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-82749132021-07-27 Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study Mazzucchelli, Ramón Rodríguez-Martín, Sara García-Vadillo, Alberto Gil, Miguel Rodríguez-Miguel, Antonio Barreira-Hernández, Diana García-Lledó, Alberto de Abajo, Francisco J. PLoS One Research Article OBJECTIVE: To test the hypothesis that the use of chondroitin sulfate (CS) or glucosamine reduces the risk of acute myocardial infarction (AMI). DESIGN: Case-control study nested in a primary cohort of patients aged 40 to 99 years, using the database BIFAP during the 2002–2015 study period. From this cohort, we identified incident cases of AMI and randomly selected five controls per case, matched by exact age, gender, and index date. Adjusted odds ratios (AOR) and 95% confidence interval (CI) were computed through a conditional logistic regression. Only new users of CS or glucosamine were considered. RESULTS: A total of 23,585 incident cases of AMI and 117,405 controls were included. Of them, 89 cases (0.38%) and 757 controls (0.64%) were current users of CS at index date, yielding an AOR of 0.57 (95%CI: 0.46–0.72). The reduced risk among current users was observed in both short-term (<365 days, AOR = 0.58; 95%CI: 0.45–0.75) and long-term users (>364 days AOR = 0.56; 95%CI:0.36–0.87), in both sexes (men, AOR = 0.52; 95%CI:0.38–0.70; women, AOR = 0.65; 95%CI:0.46–0.91), in individuals over or under 70 years of age (AOR = 0.54; 95%CI:0.38–0.77, and AOR = 0.61; 95%CI:0.45–0.82, respectively) and in individuals at intermediate (AOR = 0.65; 95%CI:0.48–0.91) and high cardiovascular risk (AOR = 0.48; 95%CI:0.27–0.83), but not in those at low risk (AOR = 1.11; 95%CI:0.48–2.56). In contrast, the current use of glucosamine was not associated with either increased or decreased risk of AMI (AOR = 0.86; 95%CI:0.66–1.08). CONCLUSIONS: Our results support a cardioprotective effect of CS, while glucosamine seems to be neutral. The protection was remarkable among subgroups at high cardiovascular risk. Public Library of Science 2021-07-12 /pmc/articles/PMC8274913/ /pubmed/34252115 http://dx.doi.org/10.1371/journal.pone.0253932 Text en © 2021 Mazzucchelli et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Mazzucchelli, Ramón
Rodríguez-Martín, Sara
García-Vadillo, Alberto
Gil, Miguel
Rodríguez-Miguel, Antonio
Barreira-Hernández, Diana
García-Lledó, Alberto
de Abajo, Francisco J.
Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study
title Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study
title_full Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study
title_fullStr Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study
title_full_unstemmed Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study
title_short Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study
title_sort risk of acute myocardial infarction among new users of chondroitin sulfate: a nested case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274913/
https://www.ncbi.nlm.nih.gov/pubmed/34252115
http://dx.doi.org/10.1371/journal.pone.0253932
work_keys_str_mv AT mazzucchelliramon riskofacutemyocardialinfarctionamongnewusersofchondroitinsulfateanestedcasecontrolstudy
AT rodriguezmartinsara riskofacutemyocardialinfarctionamongnewusersofchondroitinsulfateanestedcasecontrolstudy
AT garciavadilloalberto riskofacutemyocardialinfarctionamongnewusersofchondroitinsulfateanestedcasecontrolstudy
AT gilmiguel riskofacutemyocardialinfarctionamongnewusersofchondroitinsulfateanestedcasecontrolstudy
AT rodriguezmiguelantonio riskofacutemyocardialinfarctionamongnewusersofchondroitinsulfateanestedcasecontrolstudy
AT barreirahernandezdiana riskofacutemyocardialinfarctionamongnewusersofchondroitinsulfateanestedcasecontrolstudy
AT garcialledoalberto riskofacutemyocardialinfarctionamongnewusersofchondroitinsulfateanestedcasecontrolstudy
AT deabajofranciscoj riskofacutemyocardialinfarctionamongnewusersofchondroitinsulfateanestedcasecontrolstudy